Inhibiting IGF-1R attenuates cell proliferation and VEGF production in IGF-1R over-expressing EGFR mutant non-small cell lung cancer cells

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Experimental Lung Research

• Publication date

  2017-01-02

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1080/01902148.2017.1282994PMID 28394654
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells

  2016cited by this paper
• The apoptotic effect of simvastatin via the upregulation of BIM in nonsmall cell lung cancer cells

  2016cited by this paper
• Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.

  2015cited by this paper
• Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival.

  2015cited by this paper
• 2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L⁸⁵⁸R/T⁷⁹⁰M).

  2015cited by this paper
• The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis

  2015cited by this paper
• Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.

  2015cited by this paper
• IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide

  2015cited by this paper
• Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors.

  2015cited by this paper
• Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression

  2014cited by this paper
• Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer

  2014cited by this paper
• Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

  2014cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

  2013cited by this paper
• RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy.

  2013cited by this paper
• Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.

  2013cited by this paper
• Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.

  2013cited by this paper
• Targeting Non-Small Cell Lung Cancer Cells by Dual Inhibition of the Insulin Receptor and the Insulin-Like Growth Factor-1 Receptor

  2013cited by this paper
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

  2012cited by this paper
• Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor

  2012cited by this paper
• HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.

  2011cited by this paper
• 18FDG-PET Predicts Pharmacodynamic Response to OSI-906, a Dual IGF-1R/IR Inhibitor, in Preclinical Mouse Models of Lung Cancer

  2011cited by this paper
• Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect.

  2011cited by this paper
• Dual Targeting of the Insulin-Like Growth Factor and Collateral Pathways in Cancer: Combating Drug Resistance

  2011cited by this paper
• Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis.

  2011cited by this paper
• The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.

  2011cited by this paper
• The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models

  2010cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

  2009cited by this paper
• Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.

  2009cited by this paper
• Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.

  2009cited by this paper
• Insulin and insulin-like growth factor signalling in neoplasia

  2008cited by this paper
• Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.

  2008cited by this paper
• Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients.

  2008cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib

  2007cited by this paper
• EGFR mutations in small-cell lung cancers in patients who have never smoked.

  2006cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper

• Exploring the Potential Association of Infectious Mononucleosis With Diffuse Large B‐Cell Lymphoma: A Mendelian Randomization and miRNA Profiling Approach

  2025influential citation
• Advances in the role of the IGF signaling system in myelodysplastic syndromes and acute myeloid leukemia

  2025cites this paper
• Regulatory mechanism of the Glabrene against non‐small cell lung cancer by suppressing FGFR3

  2024cites this paper
• Linsitinib inhibits IGF-1-induced cell proliferation and hyaluronic acid secretion by suppressing PI3K/Akt and ERK pathway in orbital fibroblasts from patients with thyroid-associated ophthalmopathy

  2024cites this paper
• Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review

  2023cites this paper
• MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma

  2023cites this paper
• Cancer risk and its association with diabetes mellitus in patients with acromegaly: two centers-based study.

  2023cites this paper
• Association Between Expression of Vitamin D Receptor and Insulin-Like Growth Factor 1 Receptor Among Breast Cancer Patients

  2023cites this paper
• Activation of Src mediates acquired cisplatin resistance in human lung carcinoma cells

  2019cites this paper
• Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells

  2019cites this paper
• MicroRNA-877 inhibits cell proliferation and invasion in non-small cell lung cancer by directly targeting IGF-1R.

  2019cites this paper
• IGF-1R inhibitor PQ401 inhibits osteosarcoma cell proliferation, migration and colony formation.

  2019cites this paper
• Expressions of IGF-1, ERK, GLUT4, IRS-1 in metabolic syndrome complicated with colorectal cancer and their associations with the clinical characteristics of CRC

  2018cites this paper
• Anti-Mucin 1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1 R siRNA to SKBR 3 Metastatic Breast Cancer Cells

  2018cites this paper
• Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?

  2018cites this paper
• MiR-99b-5p and miR-203a-3p Function as Tumor Suppressors by Targeting IGF-1R in Gastric Cancer

  2018cites this paper
• Efficacy of radiotherapy on intermediate and advanced lung cancer and its effect on dynamic changes of serum vascular endothelial growth factor and matrix metalloproteinase-9

  2018cites this paper
• IGF-1 induces the epithelial-mesenchymal transition via Stat5 in hepatocellular carcinoma

  2017cites this paper